Research programme: multiple sclerosis therapeutics - Cleveland Clinic/Sanofi GenzymeAlternative Names: MS therapeutics - Cleveland Clinic Mellen Center for Multiple Sclerosis/Sanofi Genzyme
Latest Information Update: 16 Dec 2016
At a glance
- Originator Cleveland Clinic; Genzyme Corporation
- Developer Cleveland Clinic; Sanofi Genzyme
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Multiple sclerosis
Most Recent Events
- 30 Apr 2014 Early research in Multiple sclerosis in USA (unspecified route)